These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 20687538)
1. Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. Yim H; Na K Biomacromolecules; 2010 Sep; 11(9):2387-93. PubMed ID: 20687538 [TBL] [Abstract][Full Text] [Related]
2. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells. Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756 [TBL] [Abstract][Full Text] [Related]
3. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233 [TBL] [Abstract][Full Text] [Related]
4. All-trans-retinoic acid (ATRA)-grafted polymeric gene carriers for nuclear translocation and cell growth control. Park KM; Kang HC; Cho JK; Chung IJ; Cho SH; Bae YH; Na K Biomaterials; 2009 May; 30(13):2642-52. PubMed ID: 19181377 [TBL] [Abstract][Full Text] [Related]
5. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169 [TBL] [Abstract][Full Text] [Related]
6. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide. Zheng Z; Aojula H; Clarke D J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
8. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Tang XQ; Bi H; Feng JQ; Cao JG Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636 [TBL] [Abstract][Full Text] [Related]
9. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Chavanpatil MD; Patil Y; Panyam J Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148 [TBL] [Abstract][Full Text] [Related]
11. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. Li R; Wu R; Zhao L; Wu M; Yang L; Zou H ACS Nano; 2010 Mar; 4(3):1399-408. PubMed ID: 20148593 [TBL] [Abstract][Full Text] [Related]
13. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825 [TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135 [TBL] [Abstract][Full Text] [Related]
15. Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma. Hong GY; Jeong YI; Lee SJ; Lee E; Oh JS; Lee HC Arch Pharm Res; 2011 Mar; 34(3):407-17. PubMed ID: 21547672 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895 [TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Jin J; Wang FP; Wei H; Liu G Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274 [TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]